Please ensure Javascript is enabled for purposes of website accessibility

Better Living Through Cheating

By Shannon Zimmerman - Updated Nov 11, 2016 at 4:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You can beat the market without breaking a sweat. No, really.

"No pain, no gain" is my least favorite truism, particularly when it comes to investing. "Greater risk leads to greater rewards" is the relevant maxim there, but I'm not buying it. It's entirely possible to beat the market while sleeping peacefully at night with a portfolio that includes stocks but is anchored by world-class mutual funds.

No, really
Don't get me wrong. I love researching individual stocks as much as the next Fool. That said, the lion's share of my own investment moola is parked in world-class mutual funds for a very simple reason: When it's your nest egg you're talking about, crack-ups can be painful indeed.

Just ask longtime shareholders in companies like GE (NYSE: GE), Microsoft (Nasdaq: MSFT), and Pfizer (NYSE: PFE) all of which have posted annualized losses for the 10-year period that ended with November. Indeed, even a low-cost bogey-tracking ETF like SPDRs (AMEX: SPY) has declined by roughly 1% over that period, a mark that plenty of actively managed funds have left in the dust.

What's more, if buying to hold even stocks that seemed like conservative bets at the time can lead to plenty of pain without much gain, let's not even discuss erstwhile highfliers such as Oracle (Nasdaq: ORCL), Apple (Nasdaq: AAPL) and Amgen (Nasdaq: AMGN). OK, let's do. Through Wednesday's market close, each of those companies traded at a price that's more than 30% below its five-year high. Thirty percent!

With those prominent cases in point, I think the case is clear: When it comes to buying individual stocks, the smartest path is to hold just a clutch of names that you actually have time to research and follow.

The bulk of your moola, meanwhile, should be working overtime in funds that sport the following key criteria.

  • A dirt cheap price tag. The typical fund will make you pay roughly 1.5% for the "privilege" of underperformance. Don't fall for it. With funds, you typically get what you don't pay for.
  • An experienced manager. Past performance can look great in a glossy brochure, but if a fund's track record doesn't belong to the current head honcho, it doesn't mean anything.
  • Strategic consistency. A manager who chases last year's hot properties is bad news. Look for those who've stuck to their strategic guns through thick and thin. When their style is out of favor, they can buy the kind of stocks they like at a discount.

The Foolish bottom line
Sound like a winning "cheat sheet" to you? Good deal. Go forth and invest ... Foolishly. And if you'd like to see that plan in action, click here to learn more about our newest investment service, Ready-Made Millionaire. RMM features a set-and-forget lineup built on funds that strike the profile above. And we aim to juice our returns with a clutch of individual stocks -- highly profitable companies with loads of free cash flow -- and a high-octane ETF.

Ready-Made will reopen for new members early next year. In the meantime, we invite you to come in, kick our conceptual tires, and snag -- for the low, low price of nothing -- a special free report, The 11-Minute Millionaire. Designed to help you navigate up markets and down, our Foolish write-up will provide plenty of food for thought (and action!), and we'll be sure to notify you just as soon as RMM reopens. Click here to get going.

This article was originally published Oct. 31, 2006. It has been updated.

Shannon Zimmerman owns none of the securities mentioned above. Pfizer and Microsoft are Motley Fool Inside Value choices. Pfizer is also an Income Investor selection. Apple is a Stock Advisor recommendation. You can check out the Fool's strict disclosure policy by clicking right here.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Microsoft Corporation Stock Quote
Microsoft Corporation
$291.32 (-0.26%) $0.77
Apple Inc. Stock Quote
Apple Inc.
$174.55 (0.88%) $1.52
General Electric Company Stock Quote
General Electric Company
$79.92 (-1.42%) $-1.15
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.27 (-1.18%) $0.59
Oracle Corporation Stock Quote
Oracle Corporation
$79.25 (-0.34%) $0.27
Amgen Inc. Stock Quote
Amgen Inc.
$250.58 (-0.25%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.